It doesn't but you are rather missing the importance (as the market did) of the Novartis deal. $1.7 billion in potential payments rather subdues that need. SI is discussing a commercial partnership with several big Pharma's with regard to CHF. The dreaded CR acronym is something that was relegated to the rear view mirror with Novartis and will be a speck on it if another deal announced on these results today....very likely.
I urge people to look at Fate Therapeutics in the US, that got a J&J partnership of slightly larger montetary value. That stem cell company went from less than $2 billion mkt cap on the deal to now $8.5 billion - alas I didn't have anywhere near as much money in it as I do MSB, because I consider MSB's prospects better.
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-388
-
- There are more pages in this discussion • 635 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.045(4.00%) |
Mkt cap ! $1.335B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $4.980M | 4.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 73090 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 27903 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |